CAC 40
7 628,57 -42,77 (-0,56 %) Euro Stoxx 50
4 907,30 -40,43 (-0,82 %) Dow Jones
39 150,33 +15,53 (+0,04 %) EUR/USD
1,0689 -0,0017 (-0,16 %) Gold future
2 334,70 +3,50 (+0,15 %) Bitcoin EUR
59 957,27 -178,39 (-0,30 %)
Zelira Therapeutics Limited (G1G.F)
Zelira Therapeutics Limited
101 St George's Terrace
Level 3
Perth, WA 6000
Australia
61 8 6558 0886
https://zeliratx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Description
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Zelira Therapeutics Limited en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..
